{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T20:39:16Z","timestamp":1776112756772,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jdiacomp.2026.109315","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T07:14:42Z","timestamp":1774250082000},"page":"109315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and hypoglycemia-related safety of henagliflozin or dapagliflozin as add-on to CSII in hospitalized patients with T2DM: A retrospective matched study using continuous glucose monitoring"],"prefix":"10.1016","volume":"40","author":[{"given":"Heng","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhifeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanhuan","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2026.109315_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0010","first-page":"16","article-title":"Guideline for the prevention and treatment of diabetes mellitus in China (2024 edition)","volume":"17","author":"Society C D","year":"2025","journal-title":"Chin J Diab Mellitus"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0015","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.2337\/dc23-S002","article-title":"2. classification and diagnosis of diabetes: standards of Care in Diabetes-2023","volume":"46","author":"Elsayed","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0020","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0025","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0030","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s00125-024-06107-6","article-title":"Continuous glucose monitoring in adults with type 2 diabetes: a systematic review and meta-analysis","volume":"67","author":"Jancev","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0035","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1007\/s00125-024-06250-0","article-title":"Accuracy of continuous glucose monitoring in the hospital setting: an observational study","volume":"67","author":"O\u2019connor","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0040","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1089\/dia.2021.0115","article-title":"Quality of glycemic control: assessment using relationships between metrics for safety and efficacy","volume":"23","author":"Rodbard","year":"2021","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0045","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/dom.14314","article-title":"Henagliflozin monotherapy in patients with type 2 diabetes inadequately controlled on diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Lu","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0050","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1111\/dom.14389","article-title":"Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Weng","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0055","doi-asserted-by":"crossref","DOI":"10.1038\/s41574-025-01157-1","article-title":"Advances in the management of hyperglycaemia and diabetes mellitus during hospitalization","author":"Idrees","year":"2025","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0060","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0065","first-page":"190","article-title":"Expert consensus on the clinical application of ambulatory glucose profile report (2023 edition)","volume":"16","author":"Chinese Society Of Endocrinology N I C F A M D","year":"2024","journal-title":"Chin J Diabetes Mellit"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0070","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S2213-8587(24)00220-1","article-title":"Continuous glucose monitoring-based metrics and the duration of hypoglycaemia events with once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-naive type 2 diabetes: an exploratory analysis of ONWARDS 1","volume":"12","author":"Bergenstal","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0075","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4097\/kjae.2017.70.1.22","article-title":"Understanding one-way ANOVA using conceptual figures","volume":"70","author":"Kim","year":"2017","journal-title":"Korean J Anesthesiol"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0080","doi-asserted-by":"crossref","first-page":"400","DOI":"10.2337\/dc18-1444","article-title":"Validation of time in range as an outcome measure for diabetes clinical trials","volume":"42","author":"Beck","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0085","doi-asserted-by":"crossref","DOI":"10.1093\/ejcts\/ezae283","article-title":"Tissue versus mechanical mitral valve replacement in patients aged 50-70: a propensity-matched analysis","volume":"66","author":"Fialka","year":"2024","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0090","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/j.jtho.2020.11.030","article-title":"Using propensity score matching to balance the baseline characteristics","volume":"16","author":"Liang","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0095","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12933-020-01200-7","article-title":"Comprehensive elaboration of glycemic variability in diabetic macrovascular and microvascular complications","volume":"20","author":"Sun","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0100","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/1932296819831695","article-title":"Impact of CGM on the management of hypoglycemia problems: overview and secondary analysis of the HypoDE study","volume":"13","author":"Hermanns","year":"2019","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0105","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0110","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00592-021-01686-x","article-title":"Sodium-glucose cotransporter 2 inhibitors as an add-on therapy to insulin for type 1 diabetes mellitus: Meta-analysis of randomized controlled trials","volume":"58","author":"Rao","year":"2021","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0115","article-title":"Type 2 diabetes mellitus and the gut microbiota: charting new territory for Sodium-Glucose Co-Transporter 2 inhibitors","volume":"8","author":"Stepanova","year":"2024","journal-title":"Eurasian J Med Oncol"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0120","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1089\/dia.2018.0052","article-title":"Effects of Dapagliflozin on 24-hour glycemic control in patients with type 2 diabetes: a randomized controlled trial","volume":"20","author":"Henry","year":"2018","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0125","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.44","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on hypoglycaemia in brittle diabetic patients with decreased endogenous insulin secretion","volume":"2","author":"Ogawa","year":"2019","journal-title":"Endocrinol Diabetes Metab"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0130","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa1708337","article-title":"Effects of Sotagliflozin added to insulin in patients with type 1 diabetes","volume":"377","author":"Garg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0135","article-title":"Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: a real-world systematic review and meta-analysis","volume":"16","author":"Li","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0140","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/17446651.2022.2014322","article-title":"Understanding the protective effects of SGLT2 inhibitors in type 2 diabetes patients with chronic kidney disease","volume":"17","author":"Scheen","year":"2022","journal-title":"Expert Rev Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2023.125052","article-title":"DBAN: an improved dual branch attention network combined with serum Raman spectroscopy for diagnosis of diabetic kidney disease","volume":"266","author":"Chen","year":"2024","journal-title":"Talanta"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0150","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1080\/14740338.2024.2396387","article-title":"Clinical features, treatment, and prognosis of SGLT2 inhibitors induced acute pancreatitis","volume":"24","author":"Li","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0155","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2174\/0115680096383119250307083130","article-title":"Is the use of SGLT-2 associated with an increased risk of cancer?","volume":"25","author":"Hussain","year":"2025","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0160","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1177\/10600280211071089","article-title":"A scoping review evaluating the effect of SGLT-2 inhibitors on insulin dose requirements in insulin-dependent patients with type 2 diabetes","volume":"56","author":"Moulton","year":"2022","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0165","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.2337\/dc13-3055","article-title":"Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes","volume":"37","author":"Rosenstock","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.117090","article-title":"Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: a mechanistic review","volume":"240","author":"Yaribeygi","year":"2020","journal-title":"Life Sci"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2024.108941","article-title":"Diabetes mellitus therapy in the light of oxidative stress and cardiovascular complications","volume":"39","author":"Osman","year":"2025","journal-title":"J Diabetes Complicat"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0180","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.2337\/dc18-1749","article-title":"Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials","volume":"41","author":"Rosenstock","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0185","doi-asserted-by":"crossref","first-page":"405","DOI":"10.7326\/0003-4819-156-6-201203200-00003","article-title":"Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial","volume":"156","author":"Wilding","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0190","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/6839735","article-title":"Effects of Liraglutide combined with short-term continuous subcutaneous insulin infusion on glycemic control and beta cell function in patients with newly diagnosed type 2 diabetes mellitus: a pilot study","volume":"2016","author":"Ke","year":"2016","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0195","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13113196","article-title":"The impact of the withdrawal of SGLT2 inhibitors on clinical outcomes in patients with heart failure","volume":"13","author":"Nakagaito","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0200","first-page":"435","article-title":"Health care utilization and costs associated with switching from DPP-4i to GLP-1RA or SGLT2i: an observational cohort study","volume":"27","author":"Newman","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.jdiacomp.2026.109315_bb0205","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1111\/dom.13852","article-title":"Dapagliflozin vs non-SGLT-2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE-TIMI 58 trial: a nationwide observational study","volume":"21","author":"Norhammar","year":"2019","journal-title":"Diabetes Obes Metab"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872726000607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872726000607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T19:17:17Z","timestamp":1776107837000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872726000607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1056872726000607"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2026.109315","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and hypoglycemia-related safety of henagliflozin or dapagliflozin as add-on to CSII in hospitalized patients with T2DM: A retrospective matched study using continuous glucose monitoring","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2026.109315","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026","name":"copyright","label":"Copyright"}],"article-number":"109315"}}